Maravai LifeSciences Holdings, Inc. (MRVI)
Market Cap | 603.54M |
Revenue (ttm) | 241.86M |
Net Income (ttm) | -162.71M |
Shares Out | 254.66M |
EPS (ttm) | -1.16 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 1,709,507 |
Open | 2.200 |
Previous Close | 2.210 |
Day's Range | 2.200 - 2.410 |
52-Week Range | 1.665 - 10.030 |
Beta | 0.19 |
Analysts | Hold |
Price Target | 6.84 (+188.61%) |
Earnings Date | May 12, 2025 |
About MRVI
Maravai LifeSciences Holdings, Inc., a life sciences company, provides products that enable the development of drug therapies, vaccines, drug therapies, cell and gene therapies, and diagnostics North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin and Central America. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, and oligonucleotide therapy, as well ... [Read more]
Financial Performance
In 2024, MRVI's revenue was $259.19 million, a decrease of -10.30% compared to the previous year's $288.95 million. Losses were -$144.85 million, 21.7% more than in 2023.
Financial StatementsAnalyst Forecast
According to 10 analysts, the average rating for MRVI stock is "Hold." The 12-month stock price forecast is $6.84, which is an increase of 188.61% from the latest price.
News

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Maravai LifeSciences Holdings, Inc. (MRVI) and Encourages Investors to Learn More About the Investigation
NEW YORK CITY, NY / ACCESS Newswire / May 29, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Maravai LifeSciences Holdings, Inc. ("Maravai" or "...

Maravai LifeSciences Holdings, Inc. (MRVI) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation
NEW YORK CITY, NY / ACCESS Newswire / May 27, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Maravai LifeSciences Holdings, Inc. ("Maravai" or "...

Bronstein, Gewirtz & Grossman, LLC Is Investigating Maravai LifeSciences Holdings, Inc. (MRVI) And Encourages Investors to Connect
NEW YORK CITY, NY / ACCESS Newswire / May 25, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Maravai LifeSciences Holdings, Inc. ("Maravai" or "...

Bronstein, Gewirtz & Grossman, LLC Encourages Maravai LifeSciences Holdings, Inc. (MRVI) Stockholders to Inquire about Securities Investigation
NEW YORK CITY, NY / ACCESS Newswire / May 22, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Maravai LifeSciences Holdings, Inc. ("Maravai" or "...

CORRECTION – Maravai LifeSciences Releases 2024 Sustainability Report
Accelerates product innovation, expands GMP manufacturing capacity, and deepens corporate-wide commitment to responsible growth

Maravai LifeSciencesReleases 2024 Sustainability Report
Accelerates product innovation, expands GMP manufacturing capacity, and deepens corporate-wide commitment to responsible growth

Maravai LifeSciences Releases 2024 Sustainability Report
Accelerates product innovation, expands GMP manufacturing capacity, and deepens corporate-wide commitment to responsible growth

TriLink BioTechnologies® debuts its first mRNA synthesis kit with CleanCap® capping technology; Celebrates launch with kit donations to top academic institutions
SAN DIEGO--(BUSINESS WIRE)--TriLink BioTechnologies® (TriLink®), a Maravai® LifeSciences company (NASDAQ: MRVI), is fueling the future of mRNA research — starting with a significant donation to top ac...

Bronstein, Gewirtz & Grossman, LLC Is Investigating Maravai LifeSciences Holdings, Inc. (MRVI) And Encourages Stockholders to Connect
NEW YORK CITY, NY / ACCESS Newswire / May 18, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Maravai LifeSciences Holdings, Inc. ("Maravai" or "...

Maravai LifeSciences Holdings, Inc. (MRVI) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation
NEW YORK CITY, NY / ACCESS Newswire / May 15, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Maravai LifeSciences Holdings, Inc. ("Maravai" or "...

These Analysts Slash Their Forecasts On Maravai LifeSciences Following Q1 Results
Maravai LifeSciences Holdings, Inc. MRVI reported mixed results for the first quarter on Monday.

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Maravai LifeSciences Holdings, Inc. (MRVI) and Encourages Stockholders to Learn More About the Investigation
NEW YORK CITY, NY / ACCESS Newswire / May 13, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Maravai LifeSciences Holdings, Inc. ("Maravai" or "...

Maravai LifeSciences Holdings, Inc. (MRVI) Q1 2025 Earnings Call Transcript
Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Q1 2025 Earnings Conference Call May 12, 2025 5:00 PM ET Company Participants Debra Hart - Head, IR Kevin Herde - EVP and CFO Trey Martin - CEO Becky...

Maravai Lifesciences Reports First Quarter 2025 Financial Results
SAN DIEGO, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech inn...

Bronstein, Gewirtz & Grossman, LLC Encourages Maravai LifeSciences Holdings, Inc. (MRVI) Investors to Inquire about Securities Investigation
NEW YORK CITY, NY / ACCESS Newswire / May 11, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Maravai LifeSciences Holdings, Inc. ("Maravai" or "...

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Maravai LifeSciences Holdings, Inc. (MRVI) And Encourages Investors to Reach Out
NEW YORK CITY, NY / ACCESS Newswire / May 8, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Maravai LifeSciences Holdings, Inc. ("Maravai" or "t...

MRVI Shareholders Have Opportunity to Lead the Maravai LifeSciences Holdings, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - MRVI
LOS ANGELES , May 5, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Maravai LifeSciences Holdings, Inc. ("Maravai" or "the Company") (NASDAQ: MRVI) for viol...

Maravai LifeSciences To Host Earnings Conference Call on Monday, May 12, 2025
SAN DIEGO, May 01, 2025 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to...

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Maravai LifeSciences
NEW YORK CITY, NY / ACCESS Newswire / April 19, 2025 / Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Maravai Life...

Maravai LifeSciences (MRVI) Earnings Call Raises Questions Amid Legal Allegations – Hagens Berman
SAN FRANCISCO, April 16, 2025 (GLOBE NEWSWIRE) -- Shares of Maravai LifeSciences Holdings (NASDAQ: MRVI) fell nearly 6% on March 19, 2025, following revelations that the company's financial reporting ...

Maravai LifeSciences (MRVI) Earnings Call Raises Questions Amid Legal Allegations - Hagens Berman
MRVI Investors with Losses Encouraged to Contact the Firm SAN FRANCISCO, CA / ACCESS Newswire / April 15, 2025 / Shares of Maravai LifeSciences Holdings (NASDAQ:MRVI) fell nearly 6% on March 19, 2025,...

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Maravai LifeSciences
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Maravai LifeSciences To Contact Him Directly To Discuss Their Optio...

Maravai LifeSciences Holdings, Inc. (MRVI) Q4 2024 Earnings Conference Call Transcript
Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Q4 2024 Earnings Conference Call March 20, 2025 5:00 PM ET Company Participants Deb Hart - Head, IR Kevin Herde - EVP and CFO Trey Martin - CEO Confe...

Time-Sensitive: Maravai Lifesciences (MRVI) Investors May Have Legal Claims - Act Before May 5 Deadline
WASHINGTON, DC / ACCESS Newswire / March 20, 2025 / Investors in Maravai LifeSciences Holdings, Inc. ("Maravai" or the "Company") (NASDAQ:MRVI) are encouraged to take action if they purchased shares b...

Maravai Lifesciences Reports Fourth Quarter and Full Year 2024 Financial Results
SAN DIEGO, March 18, 2025 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovator...